Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma

Cancer

Volumn 82, Issue 2, 1998, Pages 342-348

  McLaren, Duncan B ^a   McKenzie, Michael ^a   Duncan, Graeme ^a   Pickles, Tom ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Deferred management; Prostate specific antigen; Prostate specific antigen doubling time; Prostatic neoplasms; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECURRENT DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHYSICAL EXAMINATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TIME FACTORS;

EID: 0031984894     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980115)82:2<349::AID-CNCR15>3.0.CO;2-Z     Document Type: Article

References (19)

1. Johansson JE, Adami HO, Andersen SO, Bergstrom R, Holmberg L, Krusemo UB. High 10 year survival rate in patients with early, untreated prostate cancer. JAMA 1992; 267(16):2191-6.
2. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-33.
3. Stamey TA, McNeal JE, Frreiha FS, Redwine EA. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-41.
4. Stamey TA, Kablan JN, McNeal JE, Johnstone IM, Frreiha FS, Redwine EA, et al. Prostatic specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostactectomy treated patients. J Urol 1989; 141:1076-83.
5. Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:47-53.
6. Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1995;34:549-53.
7. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE. Prostate-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 1993;27:125-7.
8. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JA. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43(5):649-59.
9. Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 1994;31:21-4.
10. Carter BH, Pearson JD, Metter JE, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
11. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. Cancer 1992;71(6):2031-40.
12. Hermanek P, Sobin LH, editors. UICC TNM classification of malignant tumors. 4th edition. 2nd revision. Berlin: Springer-Verlag, 1992.
13. Gleason DF. Classification of prostatic cancer. Cancer Chemother Rep 1966;50:125.
14. Brawn PN, Ayala AG, Von Eschenbach AC. Histologic grades study of prostate adenocarcinoma; the development of a new system and comparison with other methods: a preliminary study. Cancer 1982;49:525.
15. D'Amico AV, Hanks GE. Linear regression analysis using prostate specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72:2638-43.
16. Pollack A, Zagars GK, el-Naggar AK, Terry NH. Relationship of tumor DNA- ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 1994; 44(5):711-8.
17. Bratt O, Anderson H, Bak-Jensen E, Baldetorp B, Lundgren R. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. Urology 1996;47(2):218-24.
18. Matsushima H, Hosaka Y, Suzuki M, Mizutani T, Ishizuka H, Kawabe K. bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int J Urol 1996;3(2):113-7.
19. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, et al. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993;150(1):126-31.